Zanubrutinib

Zanubrutinib, sold under the brand name Brukinsa, is a medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL).[3][7][8][9] Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.[3] It is given by mouth.[3] It was approved for medical use in the United States in November 2019.[10]... [wikipedia]